A Biomarker Model for Heart Failure Risk in Patients with Preserved Kidney Function
A recent secondary analysis published in JAMA Cardiology evaluates the EMPEROR-Preserved risk model, a biomarker-based tool, for predicting the risk of first heart failure hospitalization or cardiovascular death. The study focuses on patients with heart failure who have mildly reduced or preserved ejection fraction, a population where risk stratification is clinically challenging. The research also investigates whether the treatment effects of the medication finerenone vary according to the patient’s risk level as determined by this model, offering insights into personalized therapeutic strategies for managing chronic heart failure and its associated outcomes.
Study Significance: For nephrology professionals, this research is methodologically adjacent, highlighting the critical intersection of cardiorenal syndromes and biomarker-driven risk assessment. The findings underscore the importance of integrated models that can predict adverse cardiovascular events, which are a leading cause of morbidity in patients with chronic kidney disease (CKD). This advances the field by supporting a more nuanced approach to managing fluid overload and hypertension in patients with overlapping heart and kidney conditions, potentially informing future studies on renin–angiotensin–aldosterone system (RAAS) modulation and drug-induced kidney injury in high-risk cohorts.
Source →Stay curious. Stay informed — with Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
